Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CR-2305
- Development stage
- Preclinical
- Lead developer
- Coeurative
- Modality
- Small Molecules
01
Overview
CR-2305 is a preclinical-stage small molecule therapeutic candidate being developed by Coeurative for the treatment of acute myocardial infarction (AMI) triage care. Developed by a team with expertise in cardiac sarcomere modulation, the drug is part of a pipeline aimed at improving outcomes for patients experiencing acute cardiac events. While the specific molecular target for CR-2305 has not been publicly disclosed, Coeurative's broader platform focuses on first-in-class modulators of cardiac muscle contraction. The program is currently in the preclinical phase, with future clinical trials planned to evaluate its efficacy in the immediate management of myocardial infarction.
Beyond the preview
Go deeper on CR-2305.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CR-2305.